Roche announced its investigational antibody gantenerumab failed to meet the primary endpoints in GRADUATE I and II – two Phase III studies in Alzheimer’s disease.

“We are surprised and disappointed” that the drug did not show superiority over the placebo, Chief Executive Officer John Kollins said.

GSK is planning a Phase III trial evaluating bepirovirsen as a potential functional cure for chronic hepatitis B infection, despite the most recently released data appearing less robust than the interim analyses. The trial is expected to begin in the first half of 2023.

AbbVie’s investigational neurotoxin, designed to prevent postoperative atrial fibrillation, missed the primary endpoint in a Phase II trial, the company announced Monday.

Although the agency stated that Veru Inc’s experimental drug for COVID-19 met the main goal of reducing the death rate in a late-stage trial, it flagged a number of uncertainties with the data.

The company announced that its blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market.

Arcus Biosciences and its collaboration partner Gilead Sciences announced during Arcus’ third-quarter report that the company had modified its ARC-10 Phase III trial.

The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot’s safety, tolerability and immunogenicity, or the ability to generate immune response.

Minneapolis-based DiaMedica Therapeutics plans to conduct additional studies in order to resolve a clinical hold on its DM199 program for the treatment of acute ischemic stroke (AIS).

The number of confirmed Ebola cases in Uganda has risen to 109 and the outbreak has claimed 30 lives, Health Minister Jane Ruth Aceng said on Wednesday, adding that the government was setting up an additional treatment center.